{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:40:56Z","timestamp":1776847256788,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19dm0908001"],"award-info":[{"award-number":["JP19dm0908001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["Grant-in-Aid for Scientific Research (C): 19K08037."],"award-info":[{"award-number":["Grant-in-Aid for Scientific Research (C): 19K08037."]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Study objectives<\/jats:title>\n<jats:p>Niemann-Pick type C (NPC) is an autosomal recessive and congenital neurological disorder characterized by the accumulation of cholesterol and glycosphingolipids. Symptoms include hepatosplenomegaly, vertical supranuclear saccadic palsy, ataxia, dystonia, and dementia. Some cases frequently display narcolepsy-like symptoms, including cataplexy which was reported in 26% of all NPC patients and was more often recorded among late-infantile onset (50%) and juvenile onset (38%) patients. In this current study, we examined CSF orexin levels in the 10 patients of NPC with and without cataplexy, which supports previous findings.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Ten patients with NPC were included in the study (5 males and 5 females). NPC diagnosis was biochemically confirmed in all 10 patients, from which 8 patients with NPC1 gene were identified. We compared CSF orexin levels among NPC, narcoleptic and idiopathic hypersomnia patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Six NPC patients with cataplexy had low or intermediate orexin levels. In 4 cases without cataplexy, their orexin levels were normal. In 5 cases with Miglustat treatment, their symptoms stabilized or improved. For cases without Miglustat treatment, their conditions worsened generally. The CSF orexin levels of NPC patients were significantly higher than those of patients with narcolepsy-cataplexy and lower than those of patients with idiopathic hypersomnia, which was considered as the control group with normal CSF orexin levels.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>Our study indicates that orexin level measurements can be an early alert of potential NPC. Low or intermediate orexin levels could further decrease due to reduction in the neuronal function in the orexin system, accelerating the patients\u2019 NPC pathophysiology. However with Miglustat treatment, the orexin levels stabilized or improved, along with other general symptoms. Although the circuitry is unclear, this supports that orexin system is indeed involved in narcolepsy-cataplexy in NPC patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The NPC patients with cataplexy had low or intermediate orexin levels. In the cases without cataplexy, their orexin levels were normal. Our study suggests that orexin measurements can serve as an early alert for potential NPC; furthermore, they could be a marker of therapy monitoring during a treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01531-4","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T11:03:09Z","timestamp":1601377389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early detection of Niemann-pick disease type C with cataplexy and orexin levels: continuous observation with and without Miglustat"],"prefix":"10.1186","volume":"15","author":[{"given":"A.","family":"Imanishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kanbayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"3","key":"1531_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ana.410120313","volume":"12","author":"R Kandt","year":"1982","unstructured":"Kandt R, Emerson R, Singer H, Valle D, Moser H. Cataplexy in variant forms of Niemann-pick disease. Ann Neurol. 1982;12(3):284\u20138.","journal-title":"Ann Neurol"},{"issue":"8 Suppl","key":"1531_CR2","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1093\/sleep\/17.suppl_8.S21","volume":"17","author":"A Autret","year":"1994","unstructured":"Autret A, Lucas B, Henry-Lebras F, de Toffol B. Symptomatic narcolepsies. Sleep. 1994;17(8 Suppl):S21\u20134.","journal-title":"Sleep."},{"issue":"1","key":"1531_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11910-014-0522-0","volume":"15","author":"S Nevsimalova","year":"2015","unstructured":"Nevsimalova S, Malinova V. Cataplexy and sleep disorders in Niemann-pick type C disease. Curr Neurol Neurosci Rep. 2015 Jan;15(1):522.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1531_CR4","volume-title":"Maladie de Niemann-pick: etude biochimique de 107 cas (97 familles)","author":"M Vanier","year":"1983","unstructured":"Vanier M. Maladie de Niemann-pick: etude biochimique de 107 cas (97 familles). Lyon: Manifestations clinique et approche physiopathologique du type C; 1983."},{"issue":"1","key":"1531_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-2003-38619","volume":"34","author":"T Kanbayashi","year":"2003","unstructured":"Kanbayashi T, Abe M, Fujimoto S, Miyachi T, Takahashi T, Yano T, et al. Hypocretin deficiency in niemann-pick type C with cataplexy. Neuropediatrics. 2003;34(1):52\u20133.","journal-title":"Neuropediatrics."},{"key":"1531_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-8-12","volume":"8","author":"MC Patterson","year":"2013","unstructured":"Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12.","journal-title":"Orphanet J Rare Dis"},{"key":"1531_CR7","volume-title":"International classification of sleep disorders\u2014third edition (ICSD-3). AASM resource library [online]","author":"Medicine AAoS","year":"2014","unstructured":"Medicine AAoS. International classification of sleep disorders\u2014third edition (ICSD-3). AASM resource library [online]; 2014."},{"issue":"10","key":"1531_CR8","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00415-016-8178-0","volume":"263","author":"M Synofzik","year":"2016","unstructured":"Synofzik M, Fleszar Z, Schols L, Just J, Bauer P, Torres Martin JV, et al. Identifying Niemann-pick type C in early-onset ataxia: two quick clinical screening tools. J Neurol. 2016;263(10):1911\u20138.","journal-title":"J Neurol"},{"issue":"3","key":"1531_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ana.1130","volume":"50","author":"S Nishino","year":"2001","unstructured":"Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers G, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50(3):381\u20138.","journal-title":"Ann Neurol"},{"issue":"3","key":"1531_CR10","first-page":"184","volume":"61","author":"M Soda","year":"2011","unstructured":"Soda M, Kanno K, Oguchi H, Matsumoto J, Itagaki S, Kobayashi N, et al. A case of Niemann-pick disease type C with epilepsy, autistic symptoms, and narcolepsy associated with low CSF orexin level. Fukushima J Med Sci. 2011;61(3):184.","journal-title":"Fukushima J Med Sci"},{"issue":"5","key":"1531_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.braindev.2019.01.004","volume":"41","author":"T Kumagai","year":"2019","unstructured":"Kumagai T, Terashima H, Uchida H, Fukuda A, Kasahara M, Kosuga M, et al. A case of Niemann-pick disease type C with neonatal liver failure initially diagnosed as neonatal hemochromatosis. Brain Dev. 2019;41(5):460\u20134.","journal-title":"Brain Dev"},{"issue":"1","key":"1531_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12883-018-1124-2","volume":"18","author":"T Kawazoe","year":"2018","unstructured":"Kawazoe T, Yamamoto T, Narita A, Ohno K, Adachi K, Nanba E, et al. Phenotypic variability of Niemann-pick disease type C including a case with clinically pure schizophrenia: a case report. BMC Neurol. 2018;18(1):117.","journal-title":"BMC Neurol"},{"issue":"9197","key":"1531_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino S, Ripley B, Overeem S, Lammers G, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39\u201340.","journal-title":"Lancet."},{"issue":"3","key":"1531_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/sleep\/25.3.337","volume":"25","author":"T Kanbayashi","year":"2002","unstructured":"Kanbayashi T, Yano T, Ishiguro H, Kawanishi K, Chiba S, Aizawa R, et al. Hypocretin-1 (orexin-a) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep. 2002;25(3):337\u20139.","journal-title":"Sleep."},{"issue":"10","key":"1531_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot E, Lammers G, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553\u201362.","journal-title":"Arch Neurol"},{"issue":"6","key":"1531_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540\u20135.","journal-title":"Sleep."},{"issue":"Pt 12","key":"1531_CR17","first-page":"3477","volume":"134","author":"G Plazzi","year":"2011","unstructured":"Plazzi G, Pizza F, Palaia V, Franceschini C, Poli F, Moghadam KK, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain. 2011;134(Pt 12):3477\u201389.","journal-title":"Brain"},{"issue":"1","key":"1531_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea L, Kilduff T, Peyron C, Gao X, Foye P, Danielson P, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95(1):322\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1531_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli R, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573\u201385.","journal-title":"Cell."},{"key":"1531_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev.neuro.24.1.429","volume":"24","author":"J Willie","year":"2001","unstructured":"Willie J, Chemelli R, Sinton C, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci. 2001;24:429\u201358.","journal-title":"Annu Rev Neurosci"},{"issue":"9","key":"1531_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1531_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1365-2869.2002.00284.x","volume":"11","author":"T Kanbayashi","year":"2002","unstructured":"Kanbayashi T, Inoue Y, Chiba S, Aizawa R, Saito Y, Tsukamoto H, et al. CSF hypocretin-1 (orexin-a) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res. 2002;11(1):91\u20133.","journal-title":"J Sleep Res"},{"issue":"1","key":"1531_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/smrv.1999.0069","volume":"4","author":"S Nishino","year":"2000","unstructured":"Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev. 2000;4(1):57\u201399.","journal-title":"Sleep Med Rev"},{"key":"1531_CR24","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","volume":"57","author":"B Ripley","year":"2001","unstructured":"Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, et al. CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001;57:2253\u20138.","journal-title":"Neurology."},{"issue":"4","key":"1531_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","volume":"9","author":"S Nishino","year":"2005","unstructured":"Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system. Sleep Med Rev. 2005;9(4):269\u2013310.","journal-title":"Sleep Med Rev"},{"issue":"17","key":"1531_CR26","doi-asserted-by":"publisher","first-page":"E3526","DOI":"10.1073\/pnas.1614552114","volume":"114","author":"E Hasegawa","year":"2017","unstructured":"Hasegawa E, Maejima T, Yoshida T, Masseck OA, Herlitze S, Yoshioka M, et al. Serotonin neurons in the dorsal raphe mediate the anticataplectic action of orexin neurons by reducing amygdala activity. Proc Natl Acad Sci U S A. 2017;114(17):E3526\u2013E35.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1531_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","volume":"52","author":"S Nishino","year":"1997","unstructured":"Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52(1):27\u201378.","journal-title":"Prog Neurobiol"},{"issue":"5","key":"1531_CR28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/ajmg.a.37542","volume":"170A","author":"M Omokawa","year":"2016","unstructured":"Omokawa M, Ayabe T, Nagai T, Imanishi A, Omokawa A, Nishino S, et al. Decline of CSF orexin (hypocretin) levels in Prader-Willi syndrome. Am J Med Genet A. 2016;170A(5):1181\u20136.","journal-title":"Am J Med Genet A"},{"key":"1531_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2147\/NDT.S158651","volume":"14","author":"Y Omori","year":"2018","unstructured":"Omori Y, Kanbayashi T, Imanishi A, Tsutsui K, Sagawa Y, Kikuchi YS, et al. Orexin\/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness. Neuropsychiatr Dis Treat. 2018;14:451\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"1531_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1620\/tjem.209.263","volume":"209","author":"K Oyama","year":"2006","unstructured":"Oyama K, Takahashi T, Shoji Y, Oyamada M, Noguchi A, Tamura H, et al. Niemann-pick disease type C: cataplexy and hypocretin in cerebrospinal fluid. Tohoku J Exp Med. 2006;209(3):263\u20137.","journal-title":"Tohoku J Exp Med"},{"issue":"23","key":"1531_CR31","doi-asserted-by":"publisher","first-page":"8247","DOI":"10.1073\/pnas.82.23.8247","volume":"82","author":"PG Pentchev","year":"1985","unstructured":"Pentchev PG, Comly ME, Kruth HS, Vanier MT, Wenger DA, Patel S, et al. A defect in cholesterol esterification in Niemann-pick disease (type C) patients. Proc Natl Acad Sci U S A. 1985;82(23):8247\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1531_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1212\/CPJ.0000000000000399","volume":"7","author":"MC Patterson","year":"2017","unstructured":"Patterson MC, Clayton P, Gissen P, Anheim M, Bauer P, Bonnot O, et al. Recommendations for the detection and diagnosis of Niemann-pick disease type C: an update. Neurol Clin Pract. 2017 Dec;7(6):499\u2013511.","journal-title":"Neurol Clin Pract"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01531-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:33:45Z","timestamp":1632872025000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01531-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01531-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all patients and\/or their guardians. This study was approved by the ethics committee of the Akita University School of Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study was approved for publication by the ethics committee of the Akita University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We have no conflict of interests in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}